327,575 Shares in Quest Diagnostics Incorporated $DGX Bought by Advisors Capital Management LLC
Advisors Capital Management LLC has purchased a significant new stake of 327,575 shares in Quest Diagnostics Incorporated (NYSE:DGX) for approximately $69.43 million, representing about 0.30% of the company's stock. This move is part of broader institutional investment activity, despite recent insider selling by Quest Diagnostics executives. The article also details the company's recent financial performance, dividend announcement, and analyst ratings, with a consensus of "Moderate Buy."
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Quest Diagnostics (NYSE:DGX) has received a "Moderate Buy" consensus recommendation from 13 analysts, with an average 12-month price target of $235.31. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and declared a quarterly dividend of $0.86. Despite insider stock sales, institutional investors hold a significant portion of the company's shares.
Quest Diagnostics stock extends 2026 rally after Q2 revenue and earnings beat
Quest Diagnostics (DGX) stock continues its 2026 rally, trading near its highs after reporting strong Q2 2026 results. The company exceeded revenue expectations by 2.3% with $3.04 billion and beat earnings per share estimates, indicating effective volume growth and cost management. This performance, coupled with increasing institutional investor interest and a 36.5% year-to-date gain, reinforces confidence in its growth outlook driven by structural healthcare diagnostic trends.
Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team
Quanterix Corporation has appointed Geoff Albrecht, formerly of Quest Diagnostics, as Senior Vice President and General Manager of Diagnostics. Albrecht will lead Quanterix’s Diagnostics strategy, focusing initially on Alzheimer's Disease Diagnostics, and will be responsible for scaling the company's diagnostics portfolio into a significant revenue driver. This hire emphasizes Quanterix's commitment to making diagnostics a core part of its future growth, leveraging Albrecht's 25 years of commercial leadership experience.
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX
Tocqueville Asset Management L.P. recently acquired a new stake of 106,964 shares, valued at $22.67 million, in Quest Diagnostics Incorporated (NYSE:DGX). This makes Tocqueville Asset Management L.P. one of several institutional investors to either boost or initiate positions in DGX. The article also details recent insider stock transactions, Quest Diagnostics' financial performance, dividend announcement, and updated analyst price targets.
Mitsubishi UFJ Asset Management Co. Ltd. Acquires Shares of 268,354 Quest Diagnostics Incorporated $DGX
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake of 268,354 shares in Quest Diagnostics Incorporated, valued at approximately $56.88 million, representing 0.24% of the company. Other institutional investors have also adjusted their holdings in DGX. Wall Street analysts have issued various ratings and price targets, with a consensus of "Moderate Buy" and an average target price of $235.31 for Quest Diagnostics.
Wealthfront Advisers LLC Makes New Investment in Quest Diagnostics Incorporated $DGX
Wealthfront Advisers LLC has made a new investment in Quest Diagnostics (NYSE:DGX), purchasing 34,789 shares valued at approximately $7.4 million in the second quarter. Institutional investors now own 88.06% of the company. Quest Diagnostics recently reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend of $0.86 per share.
Deutsche Bank AG Makes New $124.18 Million Investment in Quest Diagnostics Incorporated $DGX
Deutsche Bank AG has made a significant new investment of $124.18 million in Quest Diagnostics Incorporated, acquiring 585,895 shares of the medical research company's stock. Other institutional investors have also adjusted their holdings in Quest Diagnostics, which recently reported strong Q2 earnings, beating analyst estimates. The company also announced a quarterly dividend and received several positive analyst ratings.
Quest Diagnostics stock hits a fresh high as Q2 earnings beat expectations
Quest Diagnostics (DGX) stock has reached a new 52-week high in August 2026, extending its rally after reporting strong second-quarter earnings that surpassed expectations. The company recorded $3.04 billion in revenue, a 10.2% year-over-year increase, and exceeded full-year EPS guidance, demonstrating robust operational execution and improved profitability. This performance has led to positive market momentum, with the stock trading near its peak and analysts maintaining a "Moderate Buy" consensus.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Quest Diagnostics Inc. (DGX) stock rose by 2.33% to $241.76 on Wednesday, marking its third consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index (SPX) increased by 0.21% and the Dow Jones Industrial Average (DJIA) rose by 0.22%.
Quest Diagnostics stock hits all-time high at 240.15 USD By Investing.com
Quest Diagnostics stock has reached an all-time high of $240.15, trading at 98% of its 52-week high with a 38% year-to-date return. Despite appearing overvalued by InvestingPro analysis, the company has consistently raised dividends for 15 years and recently surpassed Q2 earnings expectations, prompting Truist Securities to increase its price target to $250. This performance underscores strong investor confidence and market resilience.
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix announced that its proprietary Next Generation Flow Cytometry (NGF) assay for Multiple Myeloma Minimal Residual Disease (MM MRD) was crucial in the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS™ (iberdomide), the first approved CELMoD therapy for multiple myeloma. The assay measured the primary efficacy endpoint of MRD-negative complete response in the EXCALIBER-RRMM trial, highlighting Hematogenix's expertise in registrational oncology trials. This approval reinforces the growing importance of MRD negativity as a measure of treatment success in multiple myeloma and validates Hematogenix's specialized assay methodology.
M.D. Sass LLC Buys New Shares in Quest Diagnostics Incorporated $DGX
M.D. Sass LLC has acquired a new stake of 360,453 shares in Quest Diagnostics Incorporated (NYSE:DGX), valued at approximately $76.4 million, making it their 7th largest holding. Several other institutional investors also increased their positions in Quest Diagnostics, which comprises 88.06% institutional ownership. Despite some insider selling, analysts maintain a "Moderate Buy" rating for the stock with an average target price of $235.31.
Danica Pension Livsforsikringsaktieselskab Invests $2.26 Million in Quest Diagnostics Incorporated $DGX
Danica Pension Livsforsikringsaktieselskab has invested approximately $2.26 million in Quest Diagnostics Incorporated, acquiring 10,653 shares during the second quarter. Other institutional investors have also adjusted their holdings in DGX, with institutional ownership standing at 88.06%. Analysts have a "Moderate Buy" rating for Quest Diagnostics, with an average price target of $235.31, following strong quarterly earnings and revenue performance.
Foster & Motley Inc. Makes New $3.51 Million Investment in Quest Diagnostics Incorporated $DGX
Foster & Motley Inc. has acquired a new stake of 16,571 shares in Quest Diagnostics Incorporated, valued at approximately $3.51 million, during the second quarter. Other institutional investors have also adjusted their positions in the medical research company. Quest Diagnostics recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.
Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX
Commerzbank Aktiengesellschaft FI recently acquired a new position in Quest Diagnostics Incorporated, purchasing 6,686 shares valued at approximately $1.42 million. Other institutional investors have also adjusted their holdings, with a significant portion of the company's stock owned by hedge funds and institutional investors. Analysts have a "Moderate Buy" rating for Quest Diagnostics, with an average price target of $235.31.
Alpine Woods Capital Investors LLC Acquires New Position in Quest Diagnostics Incorporated $DGX
Alpine Woods Capital Investors LLC has acquired a new stake of 7,115 shares in Quest Diagnostics Incorporated, valued at approximately $1.51 million. This comes as other institutional investors have also adjusted their holdings in the medical research company, which currently has a market capitalization of $26.13 billion. Analysts anticipate an average of $11.15 EPS for Quest Diagnostics for the current year, with the company also recently declaring a quarterly dividend of $0.86 per share.
ELV|Elevance Health Inc|Price:399.980|Chg%:+9.740
This article provides a comprehensive stock analysis of Elevance Health Inc (ELV) from TradingKey, highlighting its stable fundamentals and significant growth potential. The company is considered fairly valued within the Healthcare Providers & Services industry and has received multiple "Buy" ratings from analysts. Despite average market performance recently, the stock is suitable for range-bound swing trading due to its sideways movement between support and resistance levels.
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks
This article analyzes the Q2 performance of healthcare providers and services stocks, highlighting top performers like McKesson and CVS Health, and the weakest, AdaptHealth. It discusses the sector's general trends, including consistent demand versus high operational costs and regulatory pressures, while also touching upon broader market risks like AI and geopolitics.
WHOOP opens blood tests to nonmembers and adds a test for signals tied to 50+ cancer types
WHOOP is expanding access to its Advanced Labs services, now making them available to non-members and adding GRAIL's Galleri® multi-cancer early detection test to its offerings. These services, powered by Quest Diagnostics, provide comprehensive blood testing and AI-powered insights, aiming to offer a deeper and earlier understanding of individual health at a more accessible price point than traditional methods. The initiative seeks to empower more people to proactively manage their health and detect potential issues, including cancer, sooner.
Occidental Asset Management LLC Invests $6.12 Million in Quest Diagnostics Incorporated $DGX
Occidental Asset Management LLC recently purchased 28,872 shares of Quest Diagnostics (NYSE:DGX) valued at approximately $6.12 million during the second quarter. This acquisition is part of broader institutional investor activity, with hedge funds and other institutional investors collectively owning 88.06% of the company's stock. Quest Diagnostics reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $235.31.
Cornerstone Advisors LLC Invests $10.01 Million in Quest Diagnostics Incorporated $DGX
Cornerstone Advisors LLC has acquired a new stake of 47,208 shares, valued at approximately $10.01 million, in Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter. Other institutional investors have also adjusted their holdings in the company. Quest Diagnostics has received a "Moderate Buy" rating from Wall Street analysts, with an average target price of $235.31, and recently announced a quarterly dividend of $0.86 per share.
GSA Capital Partners LLP Purchases Shares of 4,971 Quest Diagnostics Incorporated $DGX
GSA Capital Partners LLP recently acquired a new stake of 4,971 shares in Quest Diagnostics Incorporated, valued at approximately $1.054 million. This article details other institutional investor activities, recent analyst ratings, and insider stock transactions for Quest Diagnostics. It also provides financial performance data and dividend information for the company.
Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield
Quest Diagnostics (NYSE:DGX) is highlighted for its strong dividend quality, supported by robust profitability and financial health, rather than just its headline yield. The company earns a ChartMill Dividend Rating of 7 out of 10, with a sustainable payout ratio of 34.31% and consistent dividend growth. Multiple screening tools, including Dividend Growth Stocks and High Free Cash Flow, reinforce that DGX's dividend is well-backed by its underlying business and financial flexibility.
Insight Molecular Diagnostics advances heart transplant rejection testing with new DNA-based methods.
Insight Molecular Diagnostics is expanding its blood-based DNA test, GraftAssureDx, from kidney transplant patients to heart transplant rejection, seeking FDA approval. This development aims to improve monitoring and outcomes for heart transplant recipients by simplifying the detection of rejection. Expert insights suggest the new method has significant potential for patient management.
Quanterix (QTRX) Q2 2026 Earnings Call Transcript
Quanterix reported Q2 2026 earnings, revealing a revenue of $32.9 million, a 34% increase year-over-year but a 23% pro forma decline. The company lowered its full-year 2026 revenue guidance to $142 million-$148 million due to commercial execution challenges and market softness, pushing back its cash flow break-even target to 2027. Despite these challenges, Quanterix is reorganizing its commercial team, making strategic investments in its Alzheimer’s disease diagnostics business, and announced new leadership appointments to drive improved performance in the second half of 2026 and beyond.
Simplicity Wealth LLC Acquires New Position in Quest Diagnostics Incorporated $DGX
Simplicity Wealth LLC recently acquired a new position in Quest Diagnostics (NYSE:DGX), purchasing 22,182 shares valued at approximately $4.7 million during the second quarter. Other institutional investors also adjusted their stakes, with overall institutional ownership now at 88.06%. Quest Diagnostics reported strong quarterly earnings, beating analyst estimates with an EPS of $3.12 and a 10.2% revenue increase year-over-year.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix is reorganizing its sales teams into specialized units for spatial biology, Simoa products, and clinical-trial services to improve commercial execution. The company is also aiming for an FDA decision on its LucentAD Complete Alzheimer’s blood test by Q4, with a goal of achieving $10 million in diagnostics revenue in 2026. Despite academic and biopharma funding pressures, Quanterix anticipates flat revenue in Q3 before sequential improvement in Q4, though its cash-flow breakeven target has been pushed to next year.
ABN AMRO Bank N.V. Takes $21.52 Million Position in Quest Diagnostics Incorporated $DGX
ABN AMRO Bank N.V. recently acquired a new position in Quest Diagnostics Incorporated, purchasing 101,667 shares valued at approximately $21.52 million during the second quarter. This investment makes ABN AMRO Bank N.V. an approximate 0.09% owner of the medical research company. Other institutional investors have also adjusted their holdings in Quest Diagnostics, which currently has a "Moderate Buy" consensus rating from analysts with an average price target of $235.31.
EGY.N Stock News Today | Earnings, Events & Price Alerts
This page provides news and event updates for VAALCO Energy (EGY.N), including recent earnings reports, drilling progress in Gabon and Egypt, and investor meetings. It also lists market events and stock movements related to broader market trends, such as Middle East tensions impacting major averages. The information includes specific dates for news releases and a summary of market performance on those dates.
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp
Representative Carol Devine Miller sold stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp through her United Bank Brokerage Account. These transactions, valued between $15,001 and $50,000 each, occurred on March 10, 2025, and were disclosed as part of her congressional transparency requirements. The sales reflect her personal investment strategy rather than an assessment of the companies' performance.
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp
U.S. Representative Carol Devine Miller has disclosed the sale of stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp from her United Bank Brokerage Account. These transactions, valued between $15,001 and $50,000 each, occurred on March 10, 2025. The sales are part of her personal investment strategy and are publicly disclosed for transparency.
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp
West Virginia Representative Carol Devine Miller sold stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp from her United Bank Brokerage Account. These transactions, valued between $15,001 and $50,000 each, occurred on March 10, 2025, and were disclosed as part of transparency requirements for public officials. The article notes Pfizer's financial health and dividend history, emphasizing that such sales reflect personal investment strategies rather than company performance.
Carol Devine Miller sells stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp
Carol Devine Miller, a U.S. Representative, recently sold stocks in Pfizer, Quest Diagnostics, Target, and U.S. Bancorp from her United Bank Brokerage Account. Each transaction, which occurred on March 10, 2025, ranged from $15,001 to $50,000. These sales are part of her personal investment strategy and are disclosed for transparency as required for members of Congress.
T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A
T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly denying beneficial ownership. This filing provides key figures on their holdings and control over Quest Diagnostics shares.
Form 8K Digi Power X Inc. For: 14 August By Investing.com
This article announces that Digi Power X Inc. has filed a Form 8K on August 14th, as reported by Investing.com. The content of the Form 8K is not detailed within the provided text. The article primarily serves as a placeholder announcement for the filing.
Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX
Assenagon Asset Management S.A. increased its stake in Quest Diagnostics Incorporated by 39.1% in the second quarter, acquiring 4,334 shares and bringing its total holdings to 15,405 shares valued at approximately $3.27 million. The medical research company reported strong Q2 earnings, exceeding estimates with $3.12 EPS and a 10.2% revenue increase, and issued positive fiscal 2026 EPS guidance. Analysts currently maintain a "Moderate Buy" consensus rating for Quest Diagnostics.
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Quest Diagnostics Inc (DGX), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that DGX has a momentum score of 3.90, trading between resistance at $249.41 and support at $213.38. The analysis includes a summary of technical indicators and moving averages, concluding with a neutral signal for today based on these factors.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share that met estimates and revenues that surpassed them, leading to a slight increase in stock price. The company's net sales grew by 1% year-over-year, with strong organic growth in its Diagnostics and Spatial Biology segments. Bio-Techne is set to be acquired by Merck KGaA for $11.3 billion, and this transaction remains a key focus.
National Vision Stock Down Despite Q2 Earnings & Revenue Beat
National Vision Holdings, Inc. reported stronger-than-expected Q2 2026 earnings and revenues, with adjusted earnings per share of 25 cents beating estimates by 47.1% and net revenues rising 2.5% year over year. Despite the beat and an expanded operating margin, the company's stock fell 7.9% following the announcement. National Vision also raised the lower end of its adjusted diluted earnings guidance for 2026, narrowing its comparable store sales growth outlook.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting analyst estimates, while revenues of $321.2 million surpassed expectations. Despite some segment-specific challenges and a contraction in adjusted gross margin, the company's shares rose following the announcement. The article also highlights Bio-Techne's pending acquisition by Merck KGaA for $73 per share, representing an enterprise value of approximately $11.3 billion.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting Zacks Consensus Estimates, while net sales of $321.2 million surpassed expectations. Despite some mixed segment performances and a contraction in adjusted gross margin, the company's shares rose slightly. The article also highlights Bio-Techne's agreement to be acquired by Merck KGaA for approximately $11.3 billion, which is progressing.
Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86
Quest Diagnostics (NYSE:DGX) has declared a quarterly dividend of $0.86 per share, payable on October 21st to shareholders of record on October 6th. This dividend represents an annualized payout of $3.44 and a 1.4% yield. The company has a strong dividend history, having increased its dividend for 14 consecutive years, and analysts project its earnings will sufficiently cover future payouts.
Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6
Quest Diagnostics (DGX) announced that it will maintain its quarterly dividend at $0.86 per share. This dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. The announcement was published on August 12, 2026, by MT Newswires.
Quest Diagnostics Sets Oct. 21 Date for Cash Dividend
Quest Diagnostics (NYSE: DGX) has announced a quarterly cash dividend of $0.86 per share. The dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. This move reflects the company's commitment to providing direct cash returns to its investors.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes Care (TNDM) reported a Q2 2026 loss of 31 cents per share, which was narrower than expected, though worldwide revenues of $254.6 million missed consensus estimates. Despite the revenue miss, the company's shares rose 19.1% after the announcement, driven by increased pump shipments, favorable pharmacy-channel pricing, and improved product costs, leading to a significant expansion in gross margin. TNDM reaffirmed its 2026 sales guidance and maintains a solid cash position.
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September
The FDA's Molecular and Clinical Genetics Panel will review GRAIL's Galleri multi-cancer blood test on September 23, 2026. This blood test aims to detect cancer signals early through DNA methylation patterns and predict the cancer's origin. The application includes data from over 70,000 participants in the NHS-Galleri trial and the U.S.-based PATHFINDER 2 clinical study, positioning Galleri as a technology to identify cancers earlier, especially those without routine screening options.
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
Alcon (ALC) reported stronger-than-expected Q2 2026 core earnings and revenues, leading to a 3.2% rise in its stock price. The company saw growth across its Surgical and Vision Care segments, driven by new product launches and price increases, despite some challenges in the implantables and cataract markets. Alcon also raised its full-year 2026 profitability outlook.
Insight Molecular Diagnostics: Q2 Earnings Snapshot
The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
Labcorp (LH) is showing improved revenue growth, wider margins, and higher full-year guidance, particularly in specialty testing and biopharma services. However, its current valuation is considered rich, trading at a premium to its historical median and sub-industry multiple, which raises the bar for future execution. While the operating picture is improving, the high valuation suggests a balanced, rather than an automatic buy, approach to the stock, which currently holds a Zacks Rank #3 (Hold).
